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ABSTRACT: Deamidation has been recognized as a common
spontaneous pathway of protein degradation and a prevalent
concern in the pharmaceutical industry; deamidation caused the
reduction of protein/peptide drug efficacy and shelf life in several
cases. More importantly, deamidation of physiological proteins is
related to several human diseases and considered a “timer” for the
diseases. N-linked glycosylation has a variety of significant
biological functions, and it interestingly occurs right on the
deamidation siteasparagine. It has been perceived that N-
glycosylation could prevent deamidation, but experimental support
is still lacking for clearly understanding the role of N-glycosylation
on deamidation. Our results presented that deamidation is prevented by naturally occurring N-linked glycosylation. Glycopeptides
and corresponding nonglycosylated peptides were used to compare their deamidation rates. All the nonglycosylated peptides have
different half-lives ranging from one to 20 days, for the corresponding glycosylated peptides; all the results showed that the
deamidation reaction was significantly reduced by the introduction of N-linked glycosylation. A glycoprotein, RNase B, also showed
a significantly elongated deamidation half-life compared to nonglycosylated protein RNase A. At last, N-linked glycosylation on
INGAP-P, a therapeutic peptide, increased the deamidation half-life of INGAP-P as well as its therapeutic potency.
■ INTRODUCTION
Deamidation is a spontaneous nonenzymatic reaction of
peptides and proteins both in vivo and in vitro.1−5 Asparagine
(Asn)2,6,7 and glutamine (Gln) are the two amino acids that
are susceptible to deamidation, and Asn is much more prone to
deamidation than Gln.8 In the asparaginyl deamidation
process, Asn is converted to α-aspartic acid (Asp) and β-Asp
(isoAsp) with the loss of an amine group on its side chain
through hydrolysis of the succinimide intermediate from
different directions (Figure 1).9,10 During peptide and protein
aging, its deamidation site is switched from neutral to negative
charge, and a β-linkage in the peptide backbone is formed. The
negative charge and the new rotatable bond of β-linkage are
able to result in structural and functional disruption.11−13 For
therapeutics, deamidation is one of the most prevalent
degradation pathways of proteins and peptides, which is a
safety and efficacy concern for protein and peptide
therapeutics. For example, growth hormone releasing factor
can get a 25−500 times decrease of its potency when
deamidation happens.14 Additionally, asparaginyl deamidation
is one of the major contributors to the degradation of
monoclonal antibodies,15,16 and aggregation caused by
deamidation is another common concern for protein
therapeutics. To our knowledge, it is still difficult to avoid
deamidation of protein and peptide therapeutics on a
molecular level when they are in manufacturing, manipulation,
storage, and especially administration processes.17,18 As
proteins and peptides have grown into major therapeutics in
the market in recent years, a practical chemical method is
apparently in need to prevent deamidation to increase the
stability of peptide and protein pharmaceuticals.15,18−23
For human diseases, deamination occurred in certain
proteins involved in several human diseases, such as
Alzheimer’s,12,24,25 cataracts,13,26 and Parkinson’s.27 In terms
of the physiological system, adverse effects of deamidation
which can result in diseases6,28,29 shall be prevented or
controlled through physiological pathways. There are two
possible ways for the prevention of deamidation in
physiological systems. First, L-isoaspartyl O-methyltransferase
(PIMT) provides a method to repair deamidated pro-
teins.11,30−32 PIMT can change β-Asp to α-Asp to remove
the β-linkage, however, with the unfavorable negative charge
left on the peptide backbone. As a result, the repair of
Received: September 11, 2020
Accepted: November 20, 2020
Published: December 3, 2020
Articlespubs.acs.org/acschemicalbiology
© 2020 American Chemical Society
3197
https://dx.doi.org/10.1021/acschembio.0c00734
























































































deamidated protein cannot convert Asp back to Asn, which
means it cannot get the protein back to its original Asn type.
Second, the conformational structure of protein offers an
indirect pathway to reduce the deamidation reaction rate in
general.4 The higher order structure makes the peptide
backbone more rigid to form the succinimide intermediate;33
Asn is thus more stable than that in the flexible backbone.
Nonetheless, the deamidation rate is closely related to the
primary sequence of proteins instead of the higher order
structure. Typically, the primary sequence contributes more to
deamidation than three-dimensional structure.4 N-linked
glycosylation is one of the most abundant forms of post
translational modification, which bears essential biological
functions, such as cell−cell interaction, embryogenesis,
facilitating protein folding, and cell signaling.34,35 N-glycans
are mostly and specifically attached to Asn residue in proteins,
and N-linked glycosylation is a sequence-dependent process
with a consensus amino acid sequence of Asn-Xaa-Ser/Thr
known as a sequon.36,37 The sequon has its own preferences on
the N + 1 position, where amino acids with lower hindrance
are preferred, for example, glycine.38 Interestingly, amino acid
residues with lower steric side chains at the N + 1 position
tend to make the peptide or protein more susceptible to
deamidation, especially when glycine appears at the N + 1
position.4,39 The same reaction site of deamidation and N-
linked glycosylation inspired us to believe that N-linked
glycosylation performs a function for preventing asparaginyl
deamidation to help protect intact protein structures; large N-
glycan can serve as a steric hindrance to block the attack from
backbone nitrogen to form the succinimide intermediate
(Figure 2). Even though it has been believed that N-
glycosylation could prevent deamidation,40 experimental
support is still in need to clearly demonstrate this
phenomenon. The results of this paper demonstrated that N-
linked glycosylation prevented deamidation both in glyco-
protein and in glycopeptide. As deamidation has been
implicated as a “timer” in vivo in several cases,1,2,41 N-linked
glycosylation is herein considered as a “brake” to slow down
the “timer” to keep the functions of proteins longer, whereas
deamidation is a “timer.” Overall, our results showed that N-
linked glycosylation has the function of preventing deamida-
tion no matter if it was intentionally designed or coincidentally
happened in physiological systems.
In terms of pharmaceuticals, glycosylation has become a
principle of therapeutics discovery,42,43 and N-linked glyco-
sylation has been successfully utilized to improve pharmaco-
kinetic, pharmacodynamic, and biophysical properties of
several therapeutic proteins and antibodies.44−46 Our work
herein provides a solution to the problems caused by
deamidation to therapeutic proteins and peptides. As a
demonstration for the application of this principle in
therapeutics, a therapeutic peptide from islet neogenesis
associated protein (INGAP-P) was used to demonstrate this
strategy; our results showed that preventing deamidation and
increasing the drug potency were achieved at the same time.
Therefore, we envision that using N-linked glycosylation for
preventing deamidation will become a new principle for
glycoengineering and chemical modification for increasing the
stability of therapeutic proteins and peptides.
■ RESULTS AND DISCUSSION
Peptides Selection and Synthesis. Five peptides were
selected from glycoproteins as our study targets from the
Uniprot database. Peptide sequences were selected based on
the predication of half-lives.47,48 The sequence of peptides 1a
and GP 1 was selected from human α-1-acid glycoprotein 1.49
The sequence of peptides 2a and GP 2 was selected from
peptidyl-prolyl cis−trans isomerase FKBP10. The sequence of
Figure 1. Pathway of deamidation.
Figure 2. Deamidation Prevented by N-Linked Glycosylation
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peptides 3a, GP 3, and GP 6 was selected from
deoxyribonuclease-2-alpha. The sequence of peptides 4a and
GP 4 was selected from protein sidekick-1. The sequence of
peptides 5a and GP 5 was selected from the smoothened
homologue. In these peptides, the five sequons are NGT,
NAT, NSS, NHT, and NDS. Among them, NGT is the sequon
with the lowest steric hindrance at the N + 1 position, which
should have a faster deamidation rate than the steric amino
acids. In NSS, NHT, and NDT sequons, the hydoxy group of
serine, the imidazole group of histidine, and the carboxylic acid
group of aspartate at the N + 1 position have positive catalytic
effects on the deamidation reaction.47,50 The NAT sequon has
a more steric effect than NGT and no catalytic effect of the
alanine side chain. The corresponding five GlcNAcated
peptides were synthesized to test our prediction. On the
basis of the proposed mechanism of the deamidation reaction,
there are two favored products generated from the
deamidation reaction: one is L-aspartate, and the other one is
L-isoaspartate. Corresponding aspartate and isoaspartate
peptides were also synthesized and used as our standard
compounds to facilitate identifying the products of the
deamidation reaction of our peptides. Before we test the
deamidation reactions of our target peptides, all standard
peptides including our target peptides, asparate peptides,
isoasparate peptides, and corresponding glycopeptides were
used to determine the HPLC methods for the deamidation
test. Standard peptides of enzymatic digested RNase A and
RNase B and corresponding asparate and isoasparate peptides
were synthesized and used to determine HPLC methods for
the deamidation tests. INGAP-P and its corresponding
glycosylated peptides INGAP-P G1 and INGAP-P G2 were
also synthesized for our test (Table 1).
Preventing Deamidation by Glycosylation on NGT
Sequon. Peptide 1a with the NGT sequon has more of a
tendency towards deamidation with glycine located next to
Asn. In our incubation results, it showed that 32.6% of the
undeamidated peptide was left after 48 h incubation
(Supplementary Table S1, entry 7). We noticed that the
main degradation product of peptide 1a was a compound
which has a longer retention time than either 1b (Asp) or 1c
(isoAsp) in HPLC results, and the molecular weight was
determined by ESI-MS (Supplementary Figure S5A). It is
speculated that the degradation product is a diketopiperazine-
containing peptide, which was formed by the reaction between
the N-terminal amino group and the succinimide intermediate,
which was generated by deamidation.51,52 The deamidation
half-life of peptide 1a was calculated as 31 h with the plotted
linear equation (Supplementary Figure S6). In contrast, after 5
days of incubation of the corresponding glycopeptide GP 1
under the same conditions, the main peak was still the original
GP 1 from HPLC trace (Figure 3B). Five days is 3.8 times
longer than the half-life of peptide 1a, which suggests that the
glycosylation prevented deamidation of peptide 1a. In order to
see to what extent the glycosylation can prevent the
deamidation of peptide 1a, we extended the incubation time
to 40 days. A small peak was found in the HPLC result of 40
days of incubation, and the speculated diketopiperazine-
containing peptide was observed again after the deamidation
reaction of GP 1 (Supplementary Figure S10D,E). GP 1 was
degraded to a large extent within 40 days of incubation
(Supplementary Figure S9E). However, both of the two main
degraded products were not the deamidation products of
peptide 1a according to ESI-MS results (Supplementary Figure
S10B,C). In summary, glycosylation on the NGT sequon of
Table 1. Selected Peptides and Corresponding Glycopeptides
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GP 1 prevented the deamidation reaction of peptide 1a and
makes it more stable than peptide 1a.
Preventing Deamidation by Glycosylation on NHT
Sequon. In peptide 2a, histidine is located next to Asn and
Figure 3. HPLC analysis demonstrating an increase of the stability of glycosylated peptides compared to original peptides through preventing the
deamidation reaction: (A) HPLC analysis of 48 h incubation of peptide 1a; (B) HPLC analysis of 5 days of incubation of glycosylated peptide 1a−
GP 1; (C) HPLC analysis of 5 days of incubation of peptide 2a; (D) HPLC analysis of 5 days of incubation of glycosylated peptide 2a−GP 2; (E)
HPLC analysis of 12 days of incubation of peptide 3a; (F) HPLC analysis of 40 days of incubation of glycosylated peptide 3a−GP 3; (G) HPLC
analysis of 50 days of incubation of glycosylated peptide 3a with natural N-glycan−GP 6; (H) HPLC analysis of 9 days of incubation of peptide 4a;
(I) HPLC analysis of 10 days of incubation of glycosylated peptide 4a−GP 4; (J) HPLC analysis of 13 days of incubation of peptide 5a; (K) HPLC
analysis of 20 days of incubation of glycosylated peptide 5a−GP 5.
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provides an intramolecular basic condition to accelerate the
reaction rate.50 Regarding the steric effect of the imidazole ring
of histidine, peptide 2a should have a slower deamidation rate
than peptide 1a. As expected, the deamidation half-life of
peptide 2a was tested and calculated as 6.4 days with the
plotted linear equation (Supplementary Figure S15). In
contrast, for 5 days of incubation of GP 2 under the same
conditions, the main peak of HPLC was still the starting GP 2
peak (Figure 3D). Compared to the 5 days of incubation of
peptide 2a (Figure 3C), the deamidation rate of peptide 2a
was reduced. After a 40-days of incubation, the two
deamidated products showed up as two little peaks in
HPLC, which were identified by our standard compounds
and further by ESI-MS/MS (Supplementary Figures S19, S20).
Although we can find the deamidated products of GP 2 after a
40-days of incubation, the deamidation half-life of peptide 2a
was significantly elongated through glycosylation on the NHT
sequon.
Preventing Deamidation through Glycosylation on
NSS Sequon. For peptide 3a with the NSS sequon, the
hydroxyl methyl group of serine at the N + 1 position has a
weak catalytic effect on the deamidation reaction, and its side
chain has lower steric hidrance than peptide 2a. It was
expected that the deamidation half-life is longer than that of
peptide 1a and longer than that of peptide 2a. Just as expected,
after 12 days of incubation of peptide 3a, 53.2% of the original
peptide 3a was left (Figure 3E, Supplementary Table S3, entry
6). The deamidation half-life was calculated as 13 days with the
plotted linear equation (Supplementary Figure S25). For
glycopeptide GP 3, the deamidation rate was also significantly
slowed down to a very low extent similar to that of GP 2, no
deamidation products were observed after a 40 day incubation
period according to HPLC analysis (Figure 3F). To our
delight, the degradation of GP 3 was also at a very low level.
Therefore, it is concluded that the glycosylation on the NSS
sequon of glycopeptide GP 3 significantly prevented the
deamidation reaction of peptide 3a (Supplementary Figure
S28).
Preventing Deamidation by Glycosylation on the
NDS Sequon. Compared to peptide 3a, the side chain of
aspartate in peptide 4a with the NDS sequon has higher steric
hindrance than serine. Similarly, carboxylic acid also bears a
catalytic effect on the deamidation reaction. According to the
linear equation of selected different time points, the half-life
was calculated as 13.2 days (Supplementary Figure S33). For
comparison, the HPLC results of 9 days of incubation of
peptide 4a and 10 days of incubation of GP 4 showed that the
deamidation reaction rate of peptide 4a was decreased to a
large extent due to glycosylation (Figure 3H,I). Although there
were new little peaks of 40 days of incubation of GP 4, all the
new peaks, however, are not deamidated products based on the
HPLC results of our standard compounds (Supplementary
Figure S37). For glycopeptide GP 4, we noticed that it has the
same retention time of standard isoAsp peptide 4c, so it is
possible that we did not see one of the deamidation products
in HPLC for the incubation of GP 4. We observed that the
possible deamidated peak showed up in the MS result, but the
main MS peak is still the original GP 4 peak (Supplementary
Figure S38B,C). The ratio identified between the isoAsp
peptide and Asp peptide of the incubated peptide 4a is 4.6:1
(determined by HPLC peak areas), which indicates that the
deamidation of GP 4 should have similar results to those of the
deamidation of peptide 4a due to the same succinimide
intermediate. However, there was no Asp peak (Supplementary
Figure S37A,C) in the HPLC analysis of 40 days of incubation
of GP 4, which suggested that the amount of deamidated
isoAsp product was very little despite observation of the MS
peak of isoAsp peptide in the main GP 4 peak of HPLC.
Therefore, we concluded that the deamidation rate of GP 4 is
slowed down by glycosylation on the NDS sequon.
Preventing Deamidation by Glycosylation on NAT
Sequon. The methyl group of alanine in peptide 5a with a
NAT sequon is more steric than glycine but less than histidine,
serine, and aspartate. Additionally, in contrast to the catalytic
side chains, the methyl group cannot provide any catalytic
effect on the deamidation reaction, which leaves the steric
effect as the only factor affecting the deamidation rate of
peptide 5a. Therefore, comparing the structures of peptide 5a
to those of peptide 1a, peptide 5a is predicted to have a longer
half-life than peptide 1a. As expected, using the plotted linear
equation, the deamidation half-life of peptide 5a was calculated
as 18.78 days according to our HPLC results (Supplementary
Table S5 and Figure S43), the half-life is longer than that of
peptide 1a. Using the same incubation conditions, GP 5 with
20 days of incubation did not show any deamidation products;
in contrast however, peptide 5a with 13 days had a 37.8%
deamidation (Figure 3J,K, Supplementary Table S5, entry 7).
It should be noticed that the HPLC peak of Asp standard
peptide 5b overlapped with that of glycopeptide GP 5
(Supplementary Figure S47A), which made it possible that
one of the deamidation products could appear as the same
peak as GP 5. In order to analyze the components in the
HPLC peak of GP 5 after 40 days of incubation, we collected
the incubated GP 5 peak using HPLC and characterized the
components of the peak. The molecular weight of the
deamidated product Asp peptide appeared as a small peak
together with the main peak of GP 5 in ESI-MS spectrometry
(Supplementary Figure S48B,C). However, there was no
isoAsp peptide peak in the HPLC analysis of incubated GP 5.
In the incubation of peptide 5a, the ratio between the isoAsp
peptide and Asp peptide is 2:1 (determined by HPLC peak
areas). The result here is that the amount of isoAsp was too
little to observe, which is similar to the case of GP 4, which
suggested that the ratio of the deamidation product, Asp
peptide, in the overlapped peak is very low. Overall, we can
conclude that the glycosylation on the NAT sequon reduced
the deamidation rate of GP 5.
Deamidation Prevented by Natural Biantennary
Complex N-Glycan. Since all of the glycopeptides with one
GlcNAc have significantly reduced deamidation rates, we
speculated that large natural N-glycans should also have a
similar function. In order to test our prediction, glycopeptide
GP 6 with natural biantennary complex N-glycan was
synthesized to test the function of N-glycan in preventing
deamidation reaction. Glycopeptide GP 6 contains the same
amino acid sequence as that of peptide 3a, and it was
incubated for 10, 30, and 50 days. After 50 days of incubation,
no deamidation products were detected, and this peptide is
almost as stable as GP 3 based on HPLC results (Figure 3G).
Additionally, the biantennary complex N-glycan, especially the
two sialic acid residues, was stable enough without any
significant degradation during the 50 day course of incubation
(Supplementary Figure S50). In brief summary, the experiment
demonstrated that the natural N-glycan in GP 6 also has the
same function as GlcNAc of GP 3 for preventing the
deamidation reaction.
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Deamidation Prevention in RNase B through the
High-Mannose Type N-Linked Glycosylation. After test-
ing the preventive effect of N-glycan in glycopeptides, we
switched our focus to glycoprotein RNase B. RNase B and
RNase A contain the same amino acid sequence, and the N-
linked glycosylation can facilitate the folding process of RNase
B, which was found in the process of RNase A folding. The two
proteins have similar biological functions and the only
difference between them is the high-mannose type N-linked
glycosylation on the Asn34 residue.53 Strong basic conditions
were adopted for the incubation of RNase A and B to force the
deamidation reaction to move forward faster than that in near
neutral conditions in the above tests of peptides. RNase A was
incubated for 4 days in 0.1 M glycine−NaOH buffer with pH =
9.6 under 78 °C.54 Deamidated proteins were reported to be
studied by a bottom-up method, and trypsin was used as the
proteolytic enzyme.55−57 We applied the method in our study;
RNase A and RNase B were digested by trypsin and separated
by HPLC. Since trypsin cleavage sites are the C-terminals of
lysine and arginine, the NLTK sequence from RNase A and
RNase B would be a tryptic peptide theoretically. With the
assistance of synthesized isoDLTK and DLTK, we successfully
identified the two peptides individually and avoided potential
artifacts caused by potential succinimide formation (Supple-
mentary Figure S51−S54). We found that a large portion of
Asn34 of RNase A was deamidated according to the MS and
MS/MS results compared to that of the synthesized standard
compounds (Figure 4a and Supplementary Figure S55). For
comparison, RNase B was incubated under the same
conditions for 4 days and followed by Endo H to remove
the high-mannose-type N-glycan except for the first GlcNAc.
After trypsin digestion and collection of all HPLC fractions
according to the retention time of standard peptides, mass
spectrometry was used to analyze the reaction. From the MS
and MS/MS results compared to standard peptides (Figure 4b
and Supplementary Figure S56), the main peak of this reaction
was still GlcNAcated Asn34, and no deamidated peak was
found from MS results, which indicated that the high-
mannose-type glycan of RNase B prevented the deamidation
reaction of RNase B. Thus, it can be concluded that N-linked
glycosylation prevented the Asn34 deamidation of RNase B.
N-Linked Glycosylation, Single GlcNAc, and Bianten-
nary Complex N-Glycan, Prevents the Deamidation of
INGAP-P. After exploration of deamidation prevention
through N-linked glycosylation, we tried to apply it to
stabilizing a therapeutic peptide, namely, INGAP-P, which
has therapeutic effects on both type 1 and 2 diabetes. We
noticed that INGAP-P has an NGS sequon at its C-terminal
end. After synthesis of INGAP-P, we incubated it under the
same incubating conditions as we used above. It is found that
60% undeamidated peptide was left after 40 h of incubation
based on analytical HPLC results, and the deamidation half-life
was calculated as 55.9 h (Figure 5A, Supplementary Table S6,
entry 7 and Figure S61). In contrast, glycosylated INGAP-P
(INGAP-P G1) is more stable than the original INGAP-P.
After 30 days of incubation of INGAP-P G1, almost only one
peak of INGAP-P G1 showed up in the HPLC result (Figure
5B). However, we observed two peaks of deamidation
products based on HPLC and ESI-MS/MS results after 50
days of incubation (Figure 5C and Supplementary Figure S65).
We can conclude that GlcNAc can prevent the deamidation of
INGAP-P G1, even though few deamidation products were
detected after 50 days of incubation. The other glycosylated
INGAP-P, namely, INGAP-P G2, has the same peptide
sequence of INGAP-P. After 30 days of incubation under the
Figure 4. (a) MS identification of Asn34 deamidation of RNase A;
(b) MS identification of deamidation prevention through glyco-
sylation of Asn34 in RNase B.
Figure 5. HPLC analysis demonstrating increased stability of
glycosylated INGAP-P than that of original INGAP-P through
preventing deamidation reaction by glycosylation. INGAP-P G1 and
G2 are glycosylated INGAP-P with different N-glycans. (A) HPLC
analysis of 40 h incubation of INGAP-P; (B) HPLC analysis of 30
days of incubation of INGAP-P G1; (C) HPLC analysis of 30 days of
incubation of INGAP-P G2.
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same conditions, the biantennary complex N-glycan of
INGAP-P G2 showed a similar ability of preventing the
deamidation reaction as well as the GlcNAc of INGAP-P G1
did (Figure 5C). In summary, the deamidation rate of INGAP-
P was reduced significantly no matter whther it was through a
single GlcNAc or a biantennary complex N-glycan.
Glycosylated INGAP-P Induced Higher Cell Prolifer-
ation Compared to Unmodified INGAP-P. We hypothe-
sized that glycosylated INGAP peptides would not have any
adverse effects on cell proliferation or would even cause higher
cell proliferation in the pancreatic β-cell line RIN-m5F
compared to unmodified INGAP-P due to glycosylated
INGAP peptides’ longer half-life. We used 835 nM peptides
to treat cells since it was shown previously58 that this is the
optimal dose for cultured pancreatic β-cells. Our data showed
that treating pancreatic β-cells with glycosylated INGAP-P G2
resulted in significantly higher cell proliferation compared to
unmodified INGAP-P (a 28.6% increase; p = 0.01) (Figure 6).
We also observed a trend of increasing cell proliferation in
response to INGAP-P G1 treatment, although this difference
did not reach significance. Treatment with deaminated
INGAP-P (INGAP-D) did not reduce cellular proliferation.
Deamidated INGAP-P Significantly Reduced Insulin
Secretion. Since various studies showed that INGAP peptides
also stimulated insulin secretion in pancreatic β cells,59,60 we
performed an insulin secretion study to examine the effect of
modified INGAP peptides on glucose-stimulated insulin
secretion in the hamster insulinoma cell line HIT-T15. Our
data showed that there was no difference in basal and glucose-
stimulated insulin secretion between the control and
unmodified INGAP-P treatment. In addition, there was also
no significant difference in either basal or glucose-stimulated
insulin secretion between unmodified INGAP-P and glycosy-
lated INGAP-P peptides. However, we did observe a significant
reduction in basal insulin secretion and a tendency of reduced
glucose-stimulated insulin secretion in cells treated with
deamidated INGAP-P (INGAP-D; Figure 7). Thus, our data
suggest that deamination of INGAP-P has decreased capacity
to induce insulin secretion, possibly due to its reduced
bioactivity, and this can be prevented by glycosylation of
INGAP peptides. Therefore, glycosylated INGAP-P not only
increased the stability of INGAP-P, but also increased its
potency.
■ CONCLUSIONS
In summary, we have demonstrated the preventing effect of N-
linked glycosylation both in glycoprotein and in glycopeptides.
Asparaginyl deamidation is the main degradation pathway of
all the selected peptides before glycosylation. The deamidation
rates of all the glycopeptides were significantly prevented,
which showed that N-linked glycosylation prevents deamida-
tion of glycopeptides. The N-glycans of glycoprotein RNase B
also showed a similar preventive effect of the deamidation of
RNase B. The deamidation reaction was not totally stopped,
which means that N-linked glycosylation is to reduce the
deamidation rate to a low level instead of fully terminating it,
which could bear certain biological significances. Since Asn is
considered a “timer” for biological systems, N-linked
glycosylation can be used as a modulatory tool by the
biological system to adjust the pace of the “timer.” This work
also provides us an explanation of why glycosylated protein is
more stable than nonglycosylated protein. To be mentioned
here, N-glycosylation can prevent deamidation significantly,
but N-glycosylation is not able to protect N-glycoprotein from
other chemical degradations when the incubation time is
elongated to a certain time. However, it is still promising that
new biotechnologies can be developed to increase the half-life
of peptide and protein pharmaceuticals based on the principle
of preventing deamidation of glycopeptide and glycoprotein by
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